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Background: The long pentraxin 3 (PTX3) is a member of the pentraxin family believed to reflect vascular inflammation. The aim of this analysis 
was to assess the long-term prognostic value of PTX3 in a population of patients admitted with severe myocardial infarction (MI).
methods: Blood samples were drawn 4-6 days following admission in 282 patients. PTX3 was assessed in citrated plasma by ELISA methodology. 
The patients were divided into quartiles based on their PTX3 plasma concentration.
results: After a follow-up of 45 months, 81 of 282 patients (28.7%) had either died or suffered from a new myocardial infarction. However, there 
was no significant difference in risk of a new event between the PTX3 quartiles (data displayed in the table).
conclusion: PTX3 levels 4-6 days following admission failed to provide prognostic information in patients admitted with an MI.
Table: Risk for developing a new event comparing quartiles of PTX3, Q4-Q3 vs Q1; OR (95%CI)
PTX 3 (ng/mL) quartile Event during 45 months follow-up, n (%) OR (95% CI)
Q4 (>5.6) 18 (33.3) 1.02 (0.48-2.19)
Q3 (4.10-5.59) 27 (39.1) 1.97 (0.95-4.08)
Q2 (2.77-4.09) 19 (26.4) 1.10 (0.51-2.34)
